| SBI |
500112 |
12-May-2026 |
Inter-alia, to consider and approve the following: 1. To examine the status and decide on long term fund raising in single / multiple tranches of up to US$ 2 Billion (US$ Two Billion) under Reg-S/144A, through a public offer and/or private placement of fixed / floating rate bonds in US Dollar or any other major foreign currency during FY 2026-27 |
| Elantas Beck |
500123 |
12-May-2026 |
Quarterly Results
Elantas Beck India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve Unaudited financial results for the quarter ended on 31st March, 2026 |
| Dr Reddy's Labs |
500124 |
12-May-2026 |
Audited Results & Quarterly Results
Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve To consider the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending on March 31, 2026
Board meeting intimation for recommending Final Dividend, if any, for the Financial Year 2025-26
(As per BSE Announcement dated on: 16.04.2026) |
| Foseco India |
500150 |
12-May-2026 |
To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended March 31, 2026 |
| HLV |
500193 |
12-May-2026 |
HLV Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company has been scheduled to be held on Tuesday, May 12, 2026, inter-alia, to consider and approve Audited Financial Results of the Company for the fourth quarter and financial year ended March 31, 2026. |
| Max Financial |
500271 |
12-May-2026 |
Max Financial Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 inter alia to consider and approve In terms of Regulation 29 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday May 12 2026 inter alia to consider and approve the audited financial results of the Company (both standalone and consolidated) for the financial year ending on March 31 2026. |
| Tata Power Co. |
500400 |
12-May-2026 |
Tata Power Company Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve Audited Financial Results (both Standalone and Consolidated) of the Company and to recommend dividend, if any, for the financial year ended March 31, 2026. |
| Thomas Cook (I) |
500413 |
12-May-2026 |
Thomas Cook (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve 1. the Audited Financial Results of the Company (Standalone and Consolidated) for the fourth quarter and financial year ended March 31, 2026 along with the Report of Auditors thereon; 2. to Consider and recommend dividend on the equity shares of the Company for the financial year 2025-26. |
| Novartis India |
500672 |
12-May-2026 |
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 inter alia to consider and approve The Audited Financial Results of the company for the quarter and financial year ended March 31 2026. |
| Pfizer |
500680 |
12-May-2026 |
Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 12, 2026 inter alia, to consider, approve and take on record the financial results of the Company for the quarter and year ended March 31, 2026 and to consider recommendation of dividend, if any, for the financial year ended March 31, 2026. |